Vet Comp Orthop Traumatol 2014; 27(03): 204-209
DOI: 10.3415/VCOT-13-09-0113
Original Research
Schattauer GmbH

Survival of bone marrow mesenchymal stem cells labelled with red fluorescent protein in an ovine model of collagenase-induced tendinitis

L. Lacitignola
1   Dipartimento dell’Emergenza e dei Trapianti di Organi (D.E.T.O.), Sezione di Cliniche Veterinarie e P.A, Università degli Studi di Bari “Aldo Moro”, Valenzano, BARI, Italy
,
F. Staffieri
1   Dipartimento dell’Emergenza e dei Trapianti di Organi (D.E.T.O.), Sezione di Cliniche Veterinarie e P.A, Università degli Studi di Bari “Aldo Moro”, Valenzano, BARI, Italy
,
G. Rossi
2   Dipartimento di Scienze Veterinarie, Università degli Studi di Camerino, Facoltà di Medicina Veterinaria, Matelica (MC), Italy
,
E. Francioso
1   Dipartimento dell’Emergenza e dei Trapianti di Organi (D.E.T.O.), Sezione di Cliniche Veterinarie e P.A, Università degli Studi di Bari “Aldo Moro”, Valenzano, BARI, Italy
,
A. Crovace
1   Dipartimento dell’Emergenza e dei Trapianti di Organi (D.E.T.O.), Sezione di Cliniche Veterinarie e P.A, Università degli Studi di Bari “Aldo Moro”, Valenzano, BARI, Italy
› Author Affiliations
Further Information

Publication History

Received 15 September 2013

Accepted 09 March 2014

Publication Date:
21 December 2017 (online)

Summary

Objective: The aim of this study was to track the survival and efficacy of allogeneic bone marrow mesenchymal stem cells (BM-MSC) marked with red fluorescent protein (BMMSCRFP) in an ovine model of collagenase-induced tendinopathy.

Methods: Bone marrow was harvested from one donor sheep and BM-MSC were isolated, cultivated and transfected with red fluorescent protein (BM-MSCRFP). Collagenase was injected into both Achilles tendons in the remaining nine sheep. After two weeks the left tendon was injected with a solution of 6 x 106 BM-MSCRFP and fibrin glue, while only fibrin glue was administered to the contralateral tendon in each sheep. After three, four and six weeks the tendons were harvested and evaluated for morphology, collagen I deposition, presence of CD34+ cells, and fluorescent labelled BM-MSC.

Results: We demonstrated that delivery of BM-MSC into tendon lesions had positive effects on the injured tendons. The BM-MSCRFP survived at three, four and six weeks after treatment, leading to better quality healing of tendons as compared to the controls, where no labelled cells were detected. Interestingly, we demonstrated high expression of CD34+ cells in tendons that had been treated with BM-MSCRFP.

Clinical relevance: Mesenchymal stem cell allografts have a positive effect on tendon healing and local injection of BM-MSC directly into the tendon allows the homing of BM-MSC for good efficiency of engraftment.

 
  • References

  • 1 Dominici M, Le BK, Mueller I. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
  • 2 Webster RA, Blaber SP, Herbert BR. et al. The role of mesenchymal stem cells in veterinary therapeutics - a review. N Z Vet J 2012; 60: 265-272.
  • 3 De Miguel MP, Fuentes-Julian S, Blazquez-Martinez A. et al. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med 2012; 12: 574-591.
  • 4 Brehm W, Burk J, Delling U. et al. Stem cell-based tissue engineering in veterinary orthopaedics. Cell Tissue Res 2012; 347: 677-688.
  • 5 Stewart MC. Cell-based therapies: current issues and future directions. Vet Clin North Am Equine Pract 2011; 27: 393-399.
  • 6 Stewart MC, Stewart AA. Mesenchymal stem cells: characteristics, sources, and mechanisms of action. Vet Clin North Am Equine Pract 2011; 27: 243-261.
  • 7 Guest DJ, Smith MR, Allen WR. Equine embryonic stem-like cells and mesenchymal stromal cells have different survival rates and migration patterns following their injection into damaged superficial digital flexor tendon. Equine Vet J 2010; 42: 636-642.
  • 8 Freyman T, Polin G, Osman H. et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 2006; 27: 1114-1122.
  • 9 Barbash IM, Chouraqui P, Baron J. et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003; 108: 863-868.
  • 10 Walczak P, Zhang J, Gilad AA. et al. Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke 2008; 39: 1569-1574.
  • 11 Crovace A, Lacitignola L, Francioso E. et al. Histology and immunohistochemistry study of ovine tendon grafted with cBMSCs and BMMNCs after collagenase-induced tendinopathy. Vet Comp Orthop Traumatol 2008; 21: 329-336.
  • 12 Crovace A, Lacitignola L, Rossi G. et al. Histological and immunohistochemical evaluation of autologous cultured bone marrow mesenchymal stem cells and bone marrow mononucleated cells in collagenase-induced tendinopathy of equine superficial digital flexor tendon. Veterinary Medicine International; vol.. 2010 Article ID 250978; 2010.
  • 13 Chen L, Tredget EE, Wu PY. et al. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE. 2008 3. e1886.
  • 14 Ryan JM, Barry FP, Murphy JM. et al. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond). 2005 2. 8.
  • 15 Guest DJ, Smith MR, Allen WR. Monitoring the fate of autologous and allogeneic mesenchymal progenitor cells injected into the superficial digital flexor tendon of horses: preliminary study. Equine Vet J 2008; 40: 178-181.